ClinicalTrials.gg
RecruitingNCT07229742Updated Dec 1, 2025

A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis

A Phase 2 interventional study of SHR-2173 Injection and SHR-2173 Injection Blank Preparation in Active Lupus Nephritis, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 96 studies in Lupus Nephritis with a site in China — 43 open to participants now, 46 under way, 8 of them phase 3. Lupus Nephritis · China.

Planned enrollment
44th of 88
51 · median 51
Started
2025
with 18 others
Phase 2
19 of 96
8 open now
Primary completion
2027-06
later than 22 of 45 live
Registered
83rd of 96
by date

Among the 96 studies in Lupus Nephritis with a site in China, this one is the 44th largest by planned enrollment of the 88 interventional ones that give a count, is one of 19 that started in 2025, is one of 19 in phase 2, reaches primary completion later than 22 of the 45 other live ones, and was the 83rd registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

43 of the 96 studies in Lupus Nephritis with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Lupus Nephritis with a site in China, or all of them as a file.
02

Study summary

The study is a Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in patients with lupus nephritis (LN). It adopts a randomized, double-blind, placebo-controlled, multicenter trial design.

03

Conditions studied

  • Active Lupus Nephritis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-70 years (inclusive) at signing, regardless of sex;
  2. Body weight ≥ 40.0 kg and (BMI) ≥ 16 kg/m² to ≤ 28 kg/m² at screening;
  3. Diagnosed with systemic lupus erythematosus (SLE) per 1997 ACR criteria or 2019 EULAR/ACR classification criteria;
  4. Positive antinuclear antibody (titer ≥ 1:80) and/or anti-dsDNA antibody and/or anti-Sm antibody at screening;
  5. confirmed active lupus nephritis (LN) class III or IV ± class V by renal , per 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) standards within 1 year preceding or during screening.

Exclusion criteria

Exclusion Criteria:

  1. Received renal dialysis within 12 months preceding screening, or anticipated requirement for dialysis/renal transplantation within 6 months post-enrollment;
  2. Renal demonstrating > 50% globally sclerosed glomeruli;
  3. Active severe/unstable neuropsychiatric SLE (NPSLE);
  4. Catastrophic antiphospholipid syndrome (APS) within 12 months pre-screening, or APS-related thrombotic events (except non-catastrophic/mild APS cases with stable anticoagulation ≥12 weeks prior to screening);
  5. Non-LN renal diseases potentially confounding disease assessment (e.g., diabetic nephropathy per investigator judgment);
  6. Inflammatory/ diseases beyond SLE/LN that may interfere with efficacy/safety interpretation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
51 participants (estimated)

Study arms

  • Experimental
    SHR-2173 Injection Group

    Drug: SHR-2173 Injection

  • Placebo comparator
    SHR-2173 Injection Placebo Group

    Drug: SHR-2173 Injection Blank Preparation

Interventions

  • SHR-2173 injection.

  • DrugSHR-2173 Injection Blank Preparation

    SHR-2173 injection blank preparation.

06

What researchers measure

Primary outcomes

  1. The ratio of 24-hour urine protein-creatinine ratio (24-hour UPCR) to the baseline.

    Time frame: At Week 24.

Secondary outcomes

  1. The proportion of subjects achieving complete renal response (CRR).

    Time frame: At Week 24 and Week 52.

  2. The proportion of subjects achieving partial renal response (PRR).

    Time frame: At Week 24 and Week 52.

  3. The proportion of subjects achieving at least 50% improvement in 24-hour UPCR compared to the baseline.

    Time frame: At Week 24 and Week 52.

  4. The proportion of subjects achieving at least 25% improvement in 24-hour UPCR compared to the baseline.

    Time frame: At Week 24 and Week 52.

  5. The proportion of subjects whose 24-hour UPCR was less than 0.5 g/g.

    Time frame: At Week 24 and Week 52.

  6. The proportion of subjects whose 24-hour UPCR was less than 0.7 g/g.

    Time frame: At Week 24 and Week 52.

  7. The proportion of subjects taking prednisone or the equivalent dose of glucocorticoids ≤ 5 mg/day.

    Time frame: At Week 24 and Week 52.

  8. The proportion of subjects taking prednisone or the equivalent dose of glucocorticoids ≤ 7.5 mg/day.

    Time frame: At Week 24 and Week 52.

  9. The changes in the Chronic Disease Treatment Function Assessment - Fatigue Scale (FACIT) score relative to the baseline.

    Time frame: At Week 24 and Week 52.

  10. Adverse events (AEs).

    Time frame: Up to 52 weeks.

07

Study locations

1 of 1 sites recruiting
  • The General Hospital of the Eastern Theater Command of the People's Liberation Army of China
    Nanjing, Jiangsu 210002, China
    Recruiting
    • Zhihong Liu · Contactzhliunj@vip.163.com · +86-025-80862022
    • Zhihong Liu · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jun 2027, 19 months after the start.

Of 33 phase 2 interventional studies under Lupus Nephritis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's planned 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 17, 2025
StartActual
Nov 22, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Mar 2028
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07229742
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Nov 22, 2025
Primary completion
Jun 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Dec 1, 2025

Study contacts

Su Zhang
Contact
su.zhang.sz3@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-2173

Start the discussion